search

Active clinical trials for "Purpura, Thrombocytopenic, Idiopathic"

Results 241-250 of 380

Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia...

Immune Thrombocytopenia

The project was organized by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of different cycles of high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (ITP).

Withdrawn12 enrollment criteria

Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for...

PurpuraIdiopathic Thrombocytopenic Purpura

The project was undertaking by Qilu Hospital of Shandong University and other 13 well-known hospitals in China. In order to report the efficacy and safety of Recombinant Human thrombopoietin combining with Rituximab for the treatment of adults with primary immune thrombocytopenia (ITP), compared to conventional high-dose dexamethasone therapy.

Withdrawn12 enrollment criteria

Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia

Immune ThrombocytopeniaWarm Autoimmune Hemolytic Anemia

Some patients with antibody-mediated autoimmune hematological diseases (warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (cAIHA) and immune thrombocytopenia (ITP)) shows no or only minor and transient response to therapy despite several treatment-lines. Such patients are more likely to have a severe disease, with a higher morbidity and mortality. Hypothesis Effective depletion of autoreactive plasma cells might be the key for a curative approach of these diseases. Therefore, there is a rationale for using proteasome inhibitors (PIs) in these refractory patients. The rationale is that non-tumoral autoreactive plasma cells are rapidly targeted by proteasome inhibitors. It led us to propose a short course of dexamethasone and ixazomib (5 cycles), to evaluate the safety/efficacy of this innovative strategy of treatment. Method Prospective interventional uncontrolled single arm open study evaluating the rate of patients achieving 5 cycles of ixazomib and dexamethasone without severe toxicity and response on therapy.

Withdrawn31 enrollment criteria

Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune...

Immune Thrombocytopenia

The investigators will attempt to further increase the cure rate of ITP with medical therapy by providing maintenance therapy with Mycophenolate mofetil (MMF) to persistent/chronic ITP patients after treating them with induction therapy combining rituximab and dexamethasone. The investigators will randomly assign patients to MMF versus placebo in order to demonstrate safety (e.g., for infectious risk) and efficacy (platelet counts stably >50x109/L more than 1 year off therapy).

Withdrawn27 enrollment criteria

High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of...

Immune Thrombocytopenia

The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of thalidomide combining with high-dose dexamethasone for the treatment of adults with primary immune thrombocytopenia (ITP), compared to conventional high-dose dexamethasone mono-therapy.

Withdrawn2 enrollment criteria

A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP

Autoimmune Hemolytic AnemiaImmune Thrombocytopenia

This is a Phase 2 randomized, dose-blind, multicenter study designed to evaluate the safety, tolerability, efficacy, Pharmacokinetics (PK), and Pharmacodynamics (PD) of treatment with KZR-616 in patients with active Autoimmune Hemolytic Anemia or Immune Thrombocytopenia.

Withdrawn26 enrollment criteria

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune...

Primary Immune Thrombocytopenia (ITP)

This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in patients with primary ITP.

Withdrawn30 enrollment criteria

Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults...

Immune Thrombocytopenia

This study will evaluate the safety and efficacy of avatrombopag in subjects with a confirmed diagnosis of primary ITP (≤6 months duration) over 26 weeks of treatment, and also evaluate the incidence of ITP remission.

Withdrawn22 enrollment criteria

MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration...

Immune Thrombocytopenic PurpuraIdiopathic Thrombocytopenic Purpura

The purpose of this study is to evaluate efficacy, safety and tolerability of blisibimod when administered on top of standard-of-care to subjects with Immune Thrombocytopenic Purpura (ITP).

Withdrawn14 enrollment criteria

All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial...

PurpuraIdiopathic Thrombocytopenic Purpura

The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of All-Trans Retinoic Acid (ATRA) combining with High-dose Dexamethasone for the treatment of adults with primary immune thrombocytopenia (ITP), compared to conventional high-dose dexamethasone therapy.

Withdrawn11 enrollment criteria
1...242526...38

Need Help? Contact our team!


We'll reach out to this number within 24 hrs